Question
What is the most common grade ≥3 adverse event associated with TAS-102 (trifluridine/tipiracil) plus bevacizumab in your heavily pretreated patients with metastatic colorectal cancer (CRC)?
What is the most common grade ≥3 adverse event associated with TAS-102 (trifluridine/tipiracil) plus bevacizumab in your heavily pretreated patients with metastatic colorectal cancer (CRC)?